1. INTRODUCTION:

Urolithiasis is a major and increasingly prevalent disorder of the urinary tract characterized by the formation of calculi within the kidneys, ureters, or bladder. Over recent decades, its global incidence has risen substantially across both developed and developing regions, largely driven by dietary transitions, sedentary lifestyle patterns, obesity, metabolic syndrome, climate-related dehydration, and increasing life expectancy. Contemporary epidemiological data indicate that kidney stone disease now represents a significant public health concern with considerable clinical and economic consequences, including emergency admissions, recurrent pain episodes, urinary obstruction, infection risk, and progressive impairment of renal function. The growing burden of stone disease has therefore intensified interest in preventive and recurrence-focused management strategies¹.

A particularly challenging feature of urolithiasis is its marked tendency to recur. Depending on stone composition, metabolic abnormalities, hydration status, and patient adherence to preventive measures, recurrence has been reported in approximately 30–50% of patients within 5–10 years following the first episode. Individuals with recurrent disease often experience repeated hospital visits, recurrent surgical interventions, chronic anxiety, reduced quality of life, and increased healthcare expenditure. Importantly, recurrence reflects persistent pathophysiological drivers such as urinary supersaturation, hyperoxaluria, hypocitraturia, oxidative renal epithelial injury, inflammation, and crystal retention, rather than the mere presence of an isolated stone episode².

Current therapeutic approaches, including Extracorporeal Shock Wave Lithotripsy, ureteroscopy, percutaneous nephrolithotomy, and endoscopic stone extraction, have significantly improved acute stone clearance and symptomatic relief. However, surgical elimination of stones does not necessarily correct the metabolic, inflammatory, or biochemical abnormalities responsible for new stone formation. Residual fragments, persistent lithogenic urine chemistry, and poor adherence to dietary or pharmacological prophylaxis may continue to predispose patients to recurrence. Likewise, conventional preventive drugs such as thiazide diuretics, potassium citrate, and allopurinol may be limited by gastrointestinal intolerance, metabolic adverse effects, cost, or long-term compliance challenges³.

These limitations have stimulated growing interest in phytotherapeutic interventions as safer and potentially multi-target alternatives for long-term stone prevention. Medicinal plants contain structurally diverse bioactive constituents-including flavonoids, saponins, phenolic acids, terpenoids, alkaloids, and organic-acids that may beneficially modulate several stages of lithogenesis simultaneously. Reported mechanisms include enhancement of urinary flow, reduction of urinary supersaturation, inhibition of calcium oxalate nucleation and aggregation, antioxidant protection of tubular epithelium, anti-inflammatory effects, and restoration of endogenous crystallization inhibitors such as citrate and magnesium⁴.

Among the numerous botanicals investigated, Tribulus terrestris, Bryophyllum pinnatum, and Citrus sinensis-derived citrate-rich preparations have attracted particular scientific interest due to their traditional use in urinary disorders and emerging pharmacological evidence. These agents represent complementary therapeutic models targeting urinary dilution, crystal inhibition, nephroprotection, and biochemical correction. Accordingly, the present review critically examines the mechanistic basis, experimental evidence, and translational relevance of these phytotherapeutics in the prevention of recurrent urolithiasis, with emphasis on their potential integration into future evidence-based management strategies⁵.

2. LITERATURE SEARCH METHODOLOGY:

A comprehensive literature survey was conducted to identify relevant evidence concerning recurrent urolithiasis and the therapeutic potential of selected phytotherapeutic agents. Electronic databases including PubMed, Scopus, Web of Science, and Google Scholar were systematically searched for publications available between January 2000 and April 2026. The search period was selected to capture contemporary advances in kidney stone pathobiology, phytopharmacology, and translational therapeutic approaches⁶.

Search strategies employed combinations of Medical Subject Headings (MeSH), keywords, and Boolean operators such as “AND” and “OR”. Core search terms included “urolithiasis”, “nephrolithiasis”, “kidney stones”, “recurrent urolithiasis”, “calcium oxalate”, “crystal nucleation”, “phytotherapy”, “herbal medicine”, Tribulus terrestris, Bryophyllum pinnatum, Citrus sinensis, “citrate therapy”, “antiurolithiatic activity”, “nephroprotection”, and “recurrence prevention”. Reference lists of selected articles were additionally screened to identify relevant studies not captured during the primary database search.

Studies considered eligible for inclusion comprised in vitro crystallization models, in vivo experimental studies, clinical investigations, epidemiological studies, review articles, and pharmaceutical formulation studies relevant to antiurolithiatic mechanisms or recurrence prevention. Particular emphasis was placed on studies evaluating crystal inhibition, urinary biochemical modulation, antioxidant activity, anti-inflammatory effects, nephroprotection, urinary citrate enhancement, and novel dosage forms of herbal agents.

Publications lacking sufficient methodological detail, duplicate records, non-English articles without accessible translation, conference abstracts with incomplete data, and studies unrelated to urinary stone disease were excluded. Retrieved literature was critically evaluated for scientific relevance, methodological quality, translational significance, and contribution to the mechanistic understanding of phytotherapeutic strategies in recurrent urolithiasis. This approach enabled an evidence-based synthesis of currently available data while identifying key gaps requiring future investigation⁷.

3. MODERN PATHOBIOLOGY OF RECURRENT UROLITHIASIS:

Recurrent urolithiasis is no longer viewed as a purely physicochemical event resulting from urinary crystal precipitation. Current evidence supports a multifactorial disease model involving metabolic dysregulation, renal epithelial injury, inflammation, altered urinary inhibitors, microbial influences, and persistent crystal-retention mechanisms. Stone recurrence develops when these pathogenic drivers remain unresolved after the initial episode or stone removal procedure. Understanding the modern biology of recurrent stone disease is essential for designing effective long-term preventive strategies⁸.

3.1 Supersaturation and Crystal Nucleation:

Urinary supersaturation represents the fundamental initiating event in most stone-forming conditions. When the concentration of lithogenic solutes such as calcium, oxalate, phosphate, uric acid, or cystine exceeds their solubility threshold, spontaneous precipitation may occur. This process promotes crystal nucleation, followed by crystal growth and aggregation. Low urine volume, hypercalciuria, hyperoxaluria, hypocitraturia, acidic urine, and excessive sodium intake are major contributors to supersaturation⁹. Calcium oxalate remains the predominant stone component worldwide, with calcium oxalate monohydrate crystals exhibiting strong adherence properties and greater pathogenic relevance in recurrent disease.

3.2 Randall’s Plaque Biology:

Randall’s plaque is recognized as a critical nidus for calcium stone formation, particularly idiopathic calcium oxalate nephrolithiasis. These plaques originate as interstitial calcium phosphate deposits beneath the papillary urothelium and progressively enlarge over time. When exposed to urine, the plaque surface provides a scaffold for calcium oxalate overgrowth and mature stone development. Factors implicated in plaque formation include tubular calcium handling abnormalities, oxidative injury, papillary microinflammation, and altered matrix protein expression. Persistent plaque burden may explain recurrent stone formation even after apparent complete stone removal¹⁰.

3.3 Crystal Adhesion to Tubular Cells:

For clinically significant stones to develop, crystals must be retained within the kidney rather than simply excreted in urine. Injured renal tubular epithelial cells express adhesive molecules such as CD44, osteopontin, hyaluronan, and annexins that facilitate crystal attachment. Once adherent, crystals may be internalized, trigger cytotoxic responses, or accumulate into larger aggregates. Epithelial denudation and exposure of basement membrane structures further enhance retention. Therefore, crystal-cell interaction represents a central therapeutic target in recurrence prevention¹¹.

3.4 Oxidative Stress Pathways:

Oxalate exposure and crystal contact induce excessive generation of reactive oxygen species within renal tubular cells. This oxidative stress disrupts mitochondrial function, promotes lipid peroxidation, damages membranes, and activates apoptotic pathways. Cellular injury creates debris that may serve as additional nucleation surfaces for crystal growth. Reduced endogenous antioxidant defenses, including glutathione, superoxide dismutase, and catalase, have been associated with recurrent stone disease. Antioxidant strategies may therefore reduce epithelial susceptibility to repeated crystal injury¹².

3.5 NLRP3 Inflammasome and Inflammatory Signaling:

Recent studies identify crystal-induced sterile inflammation as a major contributor to nephrolithiasis progression. Calcium oxalate crystals can activate the NLRP3 inflammasome within renal cells and macrophages, leading to caspase-1 activation and release of pro-inflammatory cytokines such as interleukin-1β and interleukin-18. Additional mediators including TNF-α, NF-κB, and MCP-1 amplify leukocyte recruitment and tissue injury. Chronic low-grade inflammation may sustain papillary damage, crystal retention, and recurrent lithogenesis¹³.

3.6 Microbiome and Infection Stones:

The urinary tract is now understood to contain a dynamic microbial ecosystem rather than being sterile under normal conditions. Dysbiosis may influence oxalate metabolism, urinary pH, and inflammatory tone. Loss of oxalate-degrading organisms such as Oxalobacter formigenes has been linked with increased urinary oxalate excretion in some populations. In addition, urease-producing pathogens can generate alkaline urine and promote struvite stone formation. Biofilm-associated crystals may resist clearance and predispose to recurrence¹⁴.

3.7 Why Stones Recur:

Stone recurrence usually reflects persistence of underlying metabolic and biological abnormalities after the first episode. Common causes include inadequate hydration, uncorrected hypercalciuria or hyperoxaluria, low urinary citrate, obesity, insulin resistance, high sodium diets, recurrent urinary infection, residual stone fragments after intervention, and poor adherence to preventive medication or dietary advice. Genetic susceptibility and environmental heat exposure may further increase recurrence risk. Thus, effective long-term management requires correction of the lithogenic milieu rather than stone removal alone¹⁵.

4. WHY CURRENT THERAPIES ARE INCOMPLETE:

Contemporary management of urolithiasis has advanced substantially over the last two decades, with minimally invasive procedures and pharmacological prophylaxis improving acute stone clearance and symptom control. However, despite these therapeutic gains, recurrence rates remain clinically significant, indicating that current interventions often address the consequence of stone disease rather than its underlying biological drivers. Persistent metabolic abnormalities, incomplete stone clearance, poor treatment adherence, and long-term tolerability issues continue to limit durable prevention^16-18.

4.1 Residual Fragments After Extracorporeal Shock Wave Lithotripsy:

Extracorporeal Shock Wave Lithotripsy (ESWL) remains a widely used non-invasive modality for selected renal and ureteric calculi. Although effective in fragmenting stones, complete clearance is not always achieved. Small residual fragments, often termed clinically insignificant residual fragments, may persist within the collecting system and subsequently act as nuclei for future crystal deposition and stone regrowth. These remnants can become particularly problematic in metabolically active stone formers, thereby contributing to recurrent episodes despite technically successful treatment.

4.2 Ureteroscopy Removes the Stone, Not the Cause:

Ureteroscopy and related endourological procedures provide high stone-free rates and rapid symptom relief. Nevertheless, procedural success does not inherently correct hypercalciuria, hyperoxaluria, hypocitraturia, acidic urine, dehydration, obesity-associated risk, or inflammatory papillary changes that predispose to lithogenesis. As a result, patients may remain biologically stone-forming even after complete extraction, emphasizing the limitation of anatomy-focused treatment without adequate metabolic prevention.

4.3 Adherence Challenges with Potassium Citrate Therapy:

Potassium citrate is an established preventive therapy, particularly for hypocitraturia and recurrent calcium stones. However, long-term adherence is frequently suboptimal due to gastrointestinal discomfort, bloating, unpleasant taste, pill burden, cost, and the need for prolonged continuous administration. Inconsistent adherence may reduce urinary citrate restoration and compromise recurrence prevention, particularly in younger patients requiring multi-year therapy.

4.4 Adverse Effects of Thiazide Therapy:

Thiazide diuretics are commonly prescribed to reduce urinary calcium excretion in recurrent calcium stone formers. While effective in selected patients, chronic use may be associated with hypokalemia, hyponatremia, hyperuricemia, glucose intolerance, dizziness, fatigue, and reduced treatment persistence. These adverse effects can diminish long-term compliance and limit use in patients with metabolic comorbidities.

4.5 Economic and Healthcare Burden:

Kidney stone disease imposes substantial direct and indirect costs through emergency visits, imaging studies, surgical procedures, anesthesia, hospitalization, repeated outpatient monitoring, medication use, and productivity loss. Recurrent stone formers generate disproportionately high healthcare expenditure due to repeated interventions over time. In many settings, financial burden itself becomes a barrier to consistent preventive care and follow-up.

4.6 Recurrence Remains Common:

Even with access to modern procedural and pharmacological therapies, recurrence remains frequent because many patients do not receive individualized metabolic evaluation or sustained preventive management. Residual fragments, lifestyle relapse, inadequate hydration, poor medication adherence, and persistent biochemical risk factors collectively maintain recurrence rates. Therefore, an ideal long-term strategy should combine stone removal with safe, tolerable, multi-target prevention capable of modifying the lithogenic urinary environment. This therapeutic gap has driven growing interest in phytotherapeutic and adjunctive preventive approaches.

5. MECHANISTIC TARGETS FOR PHYTOTHERAPEUTICS:

The multifactorial pathogenesis of recurrent urolithiasis necessitates therapeutic approaches capable of modulating several biological and physicochemical pathways simultaneously. Unlike single-target pharmacological agents, phytotherapeutics contain multiple bioactive constituents that may influence urinary chemistry, crystal behavior, epithelial integrity, oxidative stress, and inflammatory signaling in a coordinated manner. This multi-mechanistic profile is particularly relevant in recurrent stone disease, where persistence of several interconnected risk factors often underlies treatment failure.

Selected medicinal plants such as Tribulus terrestris, Bryophyllum pinnatum, and Citrus sinensis-derived citrate-rich preparations appear to target complementary stages of lithogenesis. Their reported pharmacological actions include enhancement of urine flow, calcium chelation, inhibition of crystal nucleation and aggregation, antioxidant nephroprotection, anti-inflammatory activity, restoration of urinary citrate, and reduction of tubular crystal retention. Such properties support their potential use as adjunctive or preventive agents in recurrent urolithiasis¹⁹.

Table 1. Mechanistic Targets of Selected Phytotherapeutics in Recurrent Urolithiasis²⁰

Pathogenic Target	Desired Therapeutic Effect	Candidate Herb
Urinary supersaturation	Increased urine dilution and reduced ionic concentration	Tribulus terrestris
Crystal nucleation	Calcium chelation and inhibition of early crystal formation	Citrus sinensis
Oxidative epithelial injury	Antioxidant protection of renal tubular cells	Bryophyllum pinnatum
Inflammatory signaling	Suppression of cytokine-mediated tissue injury	All three agents
Tubular crystal adhesion	Cytoprotection and reduced crystal retention	Bryophyllum pinnatum
Low urinary citrate	Natural citrate supplementation and alkalinization	Citrus sinensis

6. HERBAL EVIDENCE: TRIBULUS TERRESTRIS:

Tribulus terrestris is among the most extensively investigated medicinal plants for urinary tract disorders and is traditionally employed in Ayurveda as a diuretic and antiurolithiatic remedy. Commonly known as Gokshura or Gokharu, the plant has attracted pharmacological interest due to its broad spectrum of bioactive constituents and potential multi-target effects relevant to recurrent urolithiasis. Current evidence suggests that T. terrestris may beneficially influence urinary chemistry, crystal dynamics, renal epithelial protection, and stone recurrence risk.

6.1 Phytochemical Constituents and Steroidal Saponins:

The therapeutic relevance of T. terrestris is largely attributed to its steroidal saponin fraction, which includes protodioscin, dioscin, protogracillin, tribulosin, and related furostanol or spirostanol glycosides. Among these, protodioscin is frequently considered a principal marker compound due to its abundance and reported biological activity. In addition to saponins, the plant contains flavonoids, alkaloids, tannins, phytosterols, and trace minerals that may contribute synergistically to renal protective effects. The coexistence of multiple phytoconstituents supports a systems-based pharmacological profile rather than a single-compound mechanism²¹.

6.2 Diuretic Effect and Urinary Dilution:

One of the most clinically relevant properties of T. terrestris is its reported diuretic activity. Increased urine output may reduce urinary supersaturation of calcium, oxalate, phosphate, and uric acid by dilution, thereby lowering the probability of crystal nucleation and growth. Experimental studies indicate that extracts of the plant may increase urinary volume and electrolyte excretion, possibly through mild natriuretic effects and modulation of renal tubular handling of water and ions. Since low urine volume is a dominant modifiable risk factor for recurrence, this mechanism is particularly valuable in preventive settings²².

6.3 Anti-Crystal and Antiurolithiatic Evidence:

Preclinical investigations suggest that T. terrestris may interfere with several stages of lithogenesis. In vitro studies report inhibition of calcium oxalate crystal nucleation, reduced aggregation, and alterations in crystal morphology toward less adhesive forms. Such effects may limit crystal retention within renal tubules. Chelation of free calcium ions by polyphenolic constituents and adsorption of saponins onto crystal surfaces have been proposed as possible mechanisms. Additional reductions in urinary calcium and oxalate observed in animal models further support anti-lithogenic potential.

6.4 Nephroprotective and Antioxidant Effects:

Oxalate-induced oxidative injury is increasingly recognized as a driver of recurrent stone formation. Flavonoids and phenolic constituents in T. terrestris may enhance endogenous antioxidant defenses, including superoxide dismutase, catalase, and glutathione pathways, while reducing lipid peroxidation. Preservation of renal tubular epithelial integrity may decrease crystal adhesion and inflammatory injury, thereby complementing direct anti-crystallization actions.

6.5 Preclinical Evidence:

Animal studies employing ethylene glycol- or sodium oxalate-induced urolithiasis models have demonstrated reductions in urinary oxalate, calcium, phosphate, serum creatinine, and renal crystal deposition following treatment with T. terrestris extracts. Histopathological findings frequently indicate improved tubular architecture and reduced inflammatory changes. Although study quality and extract standardization vary, the consistency of antiurolithiatic signals across multiple models supports continued translational interest²³.

6.6 Formulation Potential:

From a pharmaceutical perspective, T. terrestris is suitable for development into tablets, capsules, granules, effervescent formulations, and standardized polyherbal combinations. Marker-based standardization using protodioscin content may improve batch consistency. Future opportunities include phytosome systems, sustained-release matrices, and combination products with citrate or antioxidant botanicals designed for long-term recurrence prevention.

6.7 Translational Limitations:

Despite encouraging preclinical findings, robust human clinical evidence remains limited. Variability in extract composition, uncertain optimal dosing, inadequate pharmacokinetic data, and scarcity of randomized controlled trials currently restrict routine clinical adoption. Therefore, well-designed translational studies using standardized preparations are required before T. terrestris can be integrated into evidence-based recurrence management. Overall, Tribulus terrestris represents a promising multi-mechanistic phytotherapeutic candidate that targets urinary dilution, crystal inhibition, and renal protection-three important pillars of recurrent urolithiasis prevention.

7. HERBAL EVIDENCE: BRYOPHYLLUM PINNATUM:

Bryophyllum pinnatum, commonly referred to as Patharchatta, Panphuti, or life plant, is a traditionally valued medicinal herb extensively used in South Asian and African ethnomedicine for urinary calculi and renal disorders. Its longstanding reputation as a “stonebreaker” herb has stimulated growing scientific interest in its antiurolithiatic and nephroprotective properties. Available evidence suggests that B. pinnatum may act primarily through antioxidant renal protection, reduction of crystal adhesion, inhibition of crystal aggregation, and preservation of tubular epithelial integrity.

7.1 Phytochemical Constituents and Flavonoids:

The pharmacological profile of B. pinnatum is strongly linked to its rich flavonoid and polyphenolic composition. Reported constituents include quercetin, kaempferol, rutin, and related glycosides, together with phenolic acids, triterpenoids, sterols, and bufadienolide derivatives. Flavonoids are considered especially relevant because of their free radical scavenging, anti-inflammatory, membrane-stabilizing, and metal-chelating actions. These mechanisms are highly pertinent to calcium oxalate stone pathogenesis, where oxidative injury and epithelial dysfunction promote crystal retention²⁴.

7.2 Anti-Oxidative Renal Protection:

Oxalate exposure generates reactive oxygen species that damage renal tubular cells, impair mitochondrial function, and create surfaces favorable for crystal attachment. Polyphenolic constituents of B. pinnatum may attenuate these processes by reducing oxidative stress and restoring endogenous antioxidant systems such as superoxide dismutase, catalase, and glutathione. Reduction of lipid peroxidation and preservation of cell membrane integrity may decrease epithelial susceptibility to lithogenic injury. This antioxidant-centered mechanism differentiates B. pinnatum from predominantly diuretic or citrate-based interventions²⁵.

7.3 Anti-Adhesion Effect on Renal Tubular Cells:

Crystal attachment to injured tubular epithelium is a critical step in stone retention and recurrent growth. Experimental evidence indicates that B. pinnatum extracts may reduce crystal adherence to renal epithelial surfaces through cytoprotective effects, stabilization of cellular membranes, and attenuation of inflammatory damage. By preserving epithelial smoothness and limiting expression of crystal-binding molecules, the plant may reduce retention of microcrystals before they enlarge into clinically significant stones²⁶.

7.4 Crystal Aggregation Inhibition:

Beyond epithelial protection, B. pinnatum may directly influence urinary crystal behavior. In vitro studies have reported reductions in calcium oxalate crystal size, lower aggregation tendency, and impaired clustering of microcrystals after exposure to plant extracts. Polyphenols may interact with crystal surfaces or alter local ionic conditions, thereby limiting enlargement and agglomeration. This effect may support spontaneous passage of smaller crystals through the urinary tract²⁷.

7.5 Nephroprotective Actions:

Recurrent urolithiasis is often accompanied by tubular inflammation, interstitial injury, and mild renal dysfunction. B. pinnatum has demonstrated nephroprotective signals in experimental settings, including improvements in serum creatinine, blood urea, and renal histology. Anti-inflammatory activity, antioxidant defense, and reduced crystal burden likely act together to preserve renal function. Such properties are clinically relevant for recurrent stone formers experiencing repeated episodes of obstruction or crystal-induced renal stress.

7.6 In Vivo Evidence:

Animal studies using ethylene glycol- and sodium oxalate-induced lithiasis models have shown reductions in urinary calcium, oxalate, phosphate, renal crystal deposition, and oxidative stress markers following treatment with B. pinnatum extracts. Histopathological analyses frequently report restoration of tubular architecture and lower inflammatory infiltration. While methodologies vary and standardization remains limited, the repeated demonstration of protective effects across models supports continued investigation²⁸.

7.7 Translational and Formulation Potential:

From a formulation standpoint, B. pinnatum may be developed as standardized extracts, capsules, oral suspensions, renal support combinations, or polyherbal products paired with diuretic or citrate-rich agents. Marker-based standardization using total flavonoid content or specific phytochemical fingerprints would improve reproducibility. Advanced delivery systems may also enhance stability of polyphenolic constituents.

7.8 Current Limitations:

Despite strong ethnomedicinal relevance and promising preclinical evidence, robust clinical trials remain scarce. Optimal dose ranges, long-term safety, pharmacokinetics, and comparative efficacy versus standard prophylaxis require clarification. Further translational work is necessary before routine evidence-based clinical use can be recommended. Overall, Bryophyllum pinnatum appears particularly valuable as a renal cytoprotective and anti-adhesion phytotherapeutic candidate, complementing other agents that target urinary dilution or citrate restoration in recurrent urolithiasis²⁹.

8. CITRATE-RICH BOTANICALS: LEAD EXAMPLE CITRUS SINENSIS:

Citrate-rich botanicals have emerged as an important phytotherapeutic category in recurrent urolithiasis because citrate is one of the most potent endogenous inhibitors of calcium stone formation. Among natural dietary sources, Citrus sinensis (sweet orange) is a practical and widely consumed botanical with translational relevance for long-term prevention. Its peel and juice contain organic acids, potassium salts, flavanones, and antioxidant phytochemicals that may beneficially modify urinary chemistry and reduce lithogenic risk³⁰.

8.1 Natural Citrate Source:

Citrate forms soluble complexes with urinary calcium, thereby decreasing free ionized calcium available for calcium oxalate and calcium phosphate crystallization. Because hypocitraturia is a recognized metabolic abnormality in recurrent stone formers, natural citrate supplementation through citrus-derived botanicals represents a rational preventive strategy. Citrus sinensis is particularly attractive due to global availability, patient familiarity, and potential suitability for prolonged use.

8.2 Urinary Alkalinization:

In addition to supplying citrate, citrus-derived potassium salts may contribute to mild urinary alkalinization after metabolism. Higher urinary pH can improve citrate handling and reduce the propensity for certain stone types, particularly uric acid stones. Although the degree of alkalinization varies by formulation and metabolic context, this mechanism may complement direct calcium-binding effects in recurrent lithiasis management³¹.

8.3 Calcium Chelation and Crystal Inhibition:

Citrate acts as a physiological chelator of calcium ions, reducing supersaturation and inhibiting crystal nucleation, growth, and aggregation. By lowering free calcium activity, citrus-derived citrate may create a urinary environment less favorable for stone initiation. This mechanism closely parallels the rationale for Potassium citrate, but through a food-based or phytotherapeutic route that may improve long-term acceptability in selected patients.

8.4 Flavanones: Hesperidin and Naringin:

Beyond citrate content, Citrus sinensis contains pharmacologically relevant flavanones such as hesperidin and naringin. These compounds exhibit antioxidant and anti-inflammatory activity that may protect renal tubular epithelium from oxalate-induced injury. Preservation of epithelial integrity is important because damaged tubular surfaces facilitate crystal adhesion and retention. Thus, citrus botanicals may provide both biochemical and tissue-protective benefits.

8.5 Recurrence Prevention Potential:

Because recurrent stone disease often requires years of preventive management, interventions must be safe, affordable, and sustainable. Citrus-based strategies may offer strong real-world value as adjuncts to hydration, dietary sodium restriction, and metabolic therapy. Regular intake of citrate-rich botanicals may help improve urinary citrate levels, reduce supersaturation, and lower recurrence risk, particularly in patients with mild hypocitraturia or poor tolerance to pharmacologic citrate supplementation³².

8.6 Formulation Opportunities:

Pharmaceutical development opportunities include standardized peel extracts, citrate-enriched powders, functional beverages, sachets, nutraceutical capsules, and combination products with diuretic or antioxidant botanicals. Standardization of citrate content and flavanone profile would be essential for reproducible efficacy.

8.7 Current Limitations:

Despite strong mechanistic plausibility, variability in sugar content, dosing equivalence, citrate concentration, and patient adherence must be considered when translating citrus interventions into clinical protocols. Dedicated randomized studies using standardized preparations remain necessary. Overall, Citrus sinensis represents a compelling lead example of citrate-rich botanicals for recurrent urolithiasis prevention by combining urinary citrate enhancement, calcium chelation, mild alkalinization, and flavonoid-mediated renal protection.

9. COMPARATIVE EVIDENCE GRADING:

The translational value of phytotherapeutics in recurrent urolithiasis depends not only on traditional use or isolated mechanistic findings, but on the overall strength of evidence across four domains: biological plausibility, reproducible preclinical efficacy, available human data, and feasibility of real-world clinical adoption. Because current literature remains heterogeneous, comparative grading can help prioritize candidates for future development and clinical trials.

Among the three leading agents discussed in this review, Tribulus terrestris demonstrates broad mechanistic relevance with relatively robust preclinical support, particularly in urinary dilution, crystal inhibition, and nephroprotection. Bryophyllum pinnatum shows strong biological rationale and consistent in vivo renal protective signals, although human evidence remains scarce. Citrus sinensis offers moderate-to-high mechanistic strength with meaningful translational practicality because citrate-based prevention already aligns with established metabolic stone management.

9.1 Interpretation of Comparative Ranking:

Tribulus terrestris:

Tribulus terrestris ranks highly because it targets several dominant recurrence pathways simultaneously, including low urine volume, crystal formation, and oxidative injury. It also has a long history of use and favorable formulation flexibility. The principal limitation is the lack of rigorous randomized human trials using standardized extracts.

Bryophyllum pinnatum:

Bryophyllum pinnatum demonstrates compelling anti-adhesion, antioxidant, and nephroprotective potential. Its role may be particularly relevant in patients with epithelial injury-driven recurrence. However, translational advancement is slower because of limited clinical datasets and the need for stronger standardization frameworks.

Citrus sinensis:

Citrus sinensis benefits from a strong preventive concept centered on citrate replacement, urinary alkalinization, and broad patient acceptability. Human relevance is higher than many herbal agents because citrate therapy is already embedded in modern stone prevention paradigms. Its main limitation is that efficacy depends on preparation type, dose consistency, and patient adherence.

10. NOVEL DELIVERY SYSTEMS FOR ANTIUROLITHIATIC PHYTOTHERAPEUTICS:

Successful translation of herbal therapies for recurrent urolithiasis depends not only on pharmacological efficacy, but also on formulation science. Many phytoconstituents with promising antiurolithiatic activity exhibit poor aqueous solubility, variable gastrointestinal absorption, rapid metabolism, unpleasant taste, or inadequate urinary bioavailability. Advanced drug-delivery strategies can address these limitations by improving stability, patient adherence, dosing precision, and sustained exposure of active metabolites within the urinary tract. For this reason, formulation innovation substantially strengthens the clinical and journal relevance of phytotherapeutic research.

10.1 Effervescent Tablets:

Effervescent systems are particularly attractive for stone prevention because they combine medication delivery with increased fluid intake-an essential component of recurrence management. Formulations containing standardized herbal extracts with citrate salts may enhance palatability, promote hydration, and provide rapid dissolution. This platform is especially suitable for Citrus sinensis-derived citrate products or combination antiurolithiatic nutraceuticals.

10.2 Herbal Suspensions:

Liquid suspensions may improve usability in geriatric, pediatric, or dysphagic populations. Suspensions allow flexible dose titration and can incorporate water-dispersible extracts from Tribulus terrestris or Bryophyllum pinnatum. However, microbial stability, sedimentation control, taste masking, and preservative compatibility require careful optimization.

10.3 Phytosomes:

Phytosome technology complexes polyphenols or flavonoids with phospholipids to improve membrane permeability and oral absorption. This approach is highly relevant for poorly bioavailable flavonoids such as hesperidin, naringin, quercetin, and kaempferol. Phytosomal delivery may enhance systemic antioxidant activity and renal tissue exposure, potentially improving epithelial protection and anti-inflammatory outcomes.

10.4 Nanoemulsions:

Nanoemulsions offer improved solubilization of lipophilic phytoconstituents such as essential oils, terpenoids, and certain saponins. Their small droplet size may increase absorption, formulation stability, and uniformity. This system may be especially useful for citrus peel oils or multi-component botanical extracts where conventional dosage forms show poor dissolution.

10.5 Sustained-Release Tablets:

Sustained-release matrices may provide prolonged exposure to active phytochemicals, reduce dosing frequency, and improve adherence during long-term recurrence prevention. Controlled-release tablets could be particularly beneficial for patients requiring chronic urinary modulation through diuretic, antioxidant, or citrate-supportive mechanisms.

10.6 Standardized Capsules:

Capsules remain one of the most practical and scalable dosage forms for herbal commercialization. They permit precise dosing, improved patient convenience, and straightforward incorporation of dry standardized extracts. Marker-based standardization-such as protodioscin for Tribulus terrestris, total flavonoids for Bryophyllum pinnatum, or citrate/flavanones for Citrus sinensis-is critical for reproducibility.

Table 3. Novel Delivery Platforms for Herbal Antiurolithiatic Therapy³⁴

Delivery System	Key Advantage	Potential Application
Effervescent tablets	Hydration + rapid dissolution	Citrate-based recurrence prevention
Herbal suspensions	Flexible dosing	Pediatric / geriatric use
Phytosomes	Enhanced flavonoid absorption	Antioxidant nephroprotection
Nanoemulsions	Better lipophilic delivery	Citrus oils / complex extracts
Sustained-release tablets	Long-duration exposure	Chronic prophylaxis
Standardized capsules	Accurate dose and scalability	Routine clinical use

11. RESEARCH GAPS AND FUTURE CLINICAL PRIORITIES:

Despite growing mechanistic and preclinical support for phytotherapeutics in recurrent urolithiasis, the current evidence base remains insufficient for broad evidence-based clinical integration. Most available data derive from in vitro experiments, animal lithiasis models, observational use patterns, or heterogeneous small-scale human studies. To transition from promising adjuncts to validated therapies, several critical research gaps must be addressed.

11.1 Lack of High-Quality Randomized Controlled Trials:

The most significant limitation is the scarcity of adequately powered randomized controlled trials (RCTs). Existing clinical studies are often limited by small sample size, short duration, open-label design, inconsistent endpoints, or poorly characterized interventions. Robust placebo-controlled and comparator-controlled RCTs are required to determine true efficacy, optimal dosing, safety, and long-term tolerability.

11.2 Absence of Biomarker-Guided Trials:

Modern prevention of recurrent urolithiasis increasingly relies on metabolic phenotyping and individualized risk stratification; however, most herbal studies have not incorporated patient selection based on urinary or biochemical biomarkers. As a result, potentially responsive subgroups may remain unidentified, and therapeutic outcomes may appear inconsistent. Future clinical trials should adopt biomarker-guided enrollment and response assessment using validated parameters such as 24-hour urinary citrate, urinary calcium, urinary oxalate, urine pH, and urinary supersaturation indices. Additional evaluation of inflammatory mediators, oxidative stress biomarkers, and detailed stone composition profiling would further strengthen mechanistic interpretation. Such precision-oriented trial designs could determine which patients are most likely to benefit from specific phytotherapeutic interventions, thereby improving efficacy signals, reducing heterogeneity, and advancing personalized recurrence prevention strategies.

11.3 Limited Pharmacokinetic and Pharmacodynamic Data:

For many candidate botanicals proposed for recurrent urolithiasis management, clinically relevant pharmacokinetic and pharmacodynamic data remain limited. This represents a major barrier to evidence-based translation, as the disposition and biological activity of phytoconstituents are often insufficiently characterized in humans. Important unanswered questions include the oral bioavailability of active compounds, intestinal absorption patterns, metabolic conversion pathways, renal excretion profiles, and urinary concentrations of active metabolites at therapeutic doses. In addition, dose–response relationships, target engagement, duration of action, and the influence of food intake or concomitant medications on pharmacological activity require systematic investigation. Without robust pharmacokinetic and pharmacodynamic characterization, rational dose selection, scheduling, and formulation optimization remain difficult, thereby limiting reproducibility and clinical confidence.

11.4 No Recurrence-Focused Multicenter Trials:

Most currently available studies evaluate short-term biochemical parameters, in vitro crystallization models, or experimental animal outcomes rather than true long-term recurrence prevention. Although such endpoints are scientifically useful, they do not fully capture the clinical objective in recurrent urolithiasis, which is sustained reduction in new stone formation and related morbidity over time. Therefore, large multicenter clinical trials with adequate follow-up duration are urgently needed to generate robust and generalizable evidence. These studies should evaluate clinically meaningful outcomes such as time to recurrence, frequency of symptomatic stone events, need for surgical intervention or hospitalization, progression of stone size or burden on imaging, patient-reported quality of life, and long-term adherence to therapy. Incorporation of these endpoints would provide stronger evidence regarding the real-world preventive value of phytotherapeutic interventions.

11.5 Need for Standardized Extracts:

A major barrier to scientific reproducibility and clinical translation is the inconsistent quality of botanical raw materials and variability in extraction methodologies. Many published studies rely on crude, locally prepared, or insufficiently characterized extracts without quantitative marker profiling, making cross-study comparison and dose standardization difficult. Differences in plant source, harvesting conditions, solvent systems, processing techniques, and storage may substantially alter phytochemical composition and therapeutic activity. Future research and product development should therefore prioritize standardized formulations with validated constituent content and batch consistency. Examples include protodioscin-rich Tribulus terrestris extracts, flavonoid-standardized Bryophyllum pinnatum preparations, and citrate/flavanone-standardized Citrus sinensis formulations. Adoption of such standardized products would improve reproducibility, facilitate regulatory acceptance, and strengthen the reliability of future clinical trials.

12. FUTURE DIRECTIONS:

The future of phytotherapeutic research in recurrent urolithiasis lies in transitioning from traditional empirical use toward precision, mechanism-based, and technology-enabled interventions. As stone disease is biologically heterogeneous, next-generation prevention strategies will likely require individualized approaches that integrate metabolic profiling, advanced formulations, and computational discovery platforms. Several emerging directions may substantially enhance the translational value of herbal antiurolithiatic agents.

12.1 Omics-Guided Phytotherapy:

High-throughput omics technologies, including genomics, metabolomics, proteomics, transcriptomics, and microbiome profiling, offer a significant opportunity to redefine future strategies for recurrent urolithiasis prevention. These advanced platforms can identify individualized metabolic and molecular signatures associated with hyperoxaluria, hypocitraturia, inflammatory phenotypes, oxidative stress burden, altered microbial ecology, and increased risk of recurrent calcium stone formation. Once such signatures are characterized, phytotherapeutic interventions may be more precisely aligned with the dominant pathogenic mechanisms present in each patient. For example, citrate-supportive botanicals may be preferentially selected for individuals with hypocitraturia, antioxidant-rich botanicals for patients with oxidative epithelial injury, anti-inflammatory agents for cytokine-driven recurrence patterns, and diuretic botanicals for low-volume stone formers. This precision-based approach could improve therapeutic efficacy, reduce unnecessary empiric supplementation, and advance personalized preventive care.

12.2 Personalized Recurrence Prevention:

Current prevention strategies for recurrent urolithiasis often rely on generalized recommendations such as increased hydration, broad dietary modification, and non-specific pharmacologic prophylaxis. Although beneficial, these approaches may not adequately address the marked biological heterogeneity among stone formers. Future management models should therefore transition toward personalized recurrence prevention based on individualized clinical and metabolic profiling. Important determinants include prior stone composition history, 24-hour urine chemistry, recurrence frequency, habitual dietary pattern, coexisting obesity or metabolic syndrome, renal imaging phenotype, and tolerance to conventional medications. Within such a precision framework, phytotherapeutic agents could be selected according to specific risk biology rather than empirical or generic herbal use. For example, Tribulus terrestris may be favored in low-volume or supersaturation-prone patients, Bryophyllum pinnatum in individuals with oxidative or epithelial injury patterns, and Citrus sinensis in patients with hypocitraturia or urine acidification tendencies. This strategy may improve preventive efficacy while enhancing long-term adherence and therapeutic relevance.

12.3 Combination with Citrate Therapy:

One of the most practical near-term strategies is combining phytotherapeutics with established citrate-based prevention. Potassium citrate remains clinically valuable but may suffer from adherence limitations. Botanical adjuncts that provide antioxidant, diuretic, anti-inflammatory, or crystal-inhibitory effects could complement citrate therapy and potentially allow lower doses or better patient acceptance. Hybrid regimens may represent a realistic bridge between conventional and phytopharmaceutical care.

12.4 Nano-Delivery Systems:

Many plant-derived bioactive compounds exhibit physicochemical and pharmacokinetic limitations such as poor aqueous solubility, low gastrointestinal absorption, extensive first-pass metabolism, and rapid systemic elimination. These constraints may reduce therapeutic exposure and limit the clinical effectiveness of otherwise promising phytoconstituents in recurrent urolithiasis management. Nano-enabled delivery systems offer a valuable strategy to overcome these barriers and enhance translational utility. Potential advantages include improved oral bioavailability, targeted renal tissue distribution, sustained or controlled release of active compounds, reduced dose requirements, and enhanced stability of oxidation-sensitive or poorly soluble phytochemicals. Such improvements may increase therapeutic consistency while supporting long-term adherence. Promising platforms include phytosomes, nanoemulsions, polymeric nanoparticles, liposomes, and controlled-release matrix systems. Integration of these advanced technologies could substantially strengthen the future clinical application of antiurolithiatic phytotherapeutics.

12.5 AI-Driven Phytochemical Screening:

Artificial intelligence and machine learning have the potential to substantially accelerate discovery of novel antiurolithiatic compounds from extensive botanical and phytochemical libraries. Traditional natural-product screening is often time-consuming, resource intensive, and dependent on sequential trial-and-error experimentation. In contrast, AI-driven computational models can rapidly analyze large datasets to identify compounds with desirable mechanistic and pharmacological properties. Potential applications include prediction of crystal-growth inhibition capacity, calcium chelation affinity, anti-inflammatory signaling effects, modulation of renal transporters involved in lithogenic ion handling, and estimation of drug-likeness, pharmacokinetic behavior, or toxicity risk. Machine learning approaches may also help identify synergistic multi-herb combinations capable of targeting several pathways simultaneously. By prioritizing the most promising candidates for experimental validation, this strategy could reduce development time, lower screening costs, and accelerate translation of phytotherapeutics for recurrent urolithiasis prevention.

12.6 Integrated Future Model:

The most effective future paradigm for recurrent urolithiasis prevention will likely involve an integrated precision-medicine framework that combines advances in systems biology, pharmaceutical technology, and digital health monitoring. Rather than relying on isolated interventions, next-generation management may incorporate omics-based patient stratification to identify dominant metabolic and molecular risk pathways, enabling more accurate therapeutic selection. Artificial intelligence could then be used to identify optimized phytochemical combinations with complementary antiurolithiatic mechanisms and favorable safety profiles. These interventions should be delivered through standardized extracts to ensure reproducible phytochemical content and regulatory consistency, while nano-enabled delivery platforms may enhance bioavailability, renal targeting, and sustained therapeutic exposure. Long-term recurrence monitoring could be further strengthened through digital biomarkers, wearable hydration tracking, remote urine analytics, and serial imaging-based surveillance. Collectively, such a multidimensional model has the potential to transform phytotherapeutic prevention from empirical supplementation into a data-driven, personalized, and clinically measurable strategy for recurrent stone disease.

13. CONCLUSION:

Recurrent urolithiasis remains a major clinical challenge because current therapies frequently remove stones without fully correcting the biological processes that drive future formation. Persistent supersaturation, crystal retention, oxidative epithelial injury, inflammation, and metabolic abnormalities continue to sustain high recurrence rates despite procedural advances. This therapeutic gap highlights the need for safe, durable, and mechanism-based preventive strategies. Phytotherapeutics offer a compelling adjunctive approach because they can target multiple pathogenic pathways simultaneously. Tribulus terrestris demonstrates promise through urinary dilution, diuretic activity, and anti-crystallization effects; Bryophyllum pinnatum appears particularly relevant for antioxidant nephroprotection and reduction of crystal adhesion; and Citrus sinensis provides translational value through citrate support, urinary alkalinization, and calcium chelation. Collectively, these agents represent complementary rather than competing strategies for recurrence prevention. However, clinical adoption must be guided by stronger evidence. Standardized extracts, pharmacokinetic characterization, biomarker-driven patient selection, and multicenter recurrence-focused randomized trials are essential to validate efficacy and safety. Future integration with advanced delivery systems, precision medicine models, and AI-assisted phytochemical discovery may further enhance therapeutic impact. In summary, phytotherapeutic interventions have significant potential to evolve from traditional remedies into evidence-based components of personalized long-term management for recurrent urolithiasis.

14. REFERENCE:

1. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World Journal of Urology. 2017 Sep; 35(9):1301-20.

2. Worcester EM, Coe FL. Calcium kidney stones. New England Journal of Medicine. 2010 Sep 2; 363(10): 954-63.

3. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR. Medical management of kidney stones: AUA guideline. The Journal of Urology. 2014 Aug; 192(2): 316-24.

4. Aggarwal A, Tandon S, Singla SK, Tandon C. Diminution of oxalate induced renal tubular epithelial cell injury and inhibition of calcium oxalate crystallization in vitro by aqueous extract of Tribulus terrestris. International Braz J Urol. 2010; 36: 480-9.

5. Patel PK, Patel MA, Vyas BA, Shah DR, Gandhi TR. Antiurolithiatic activity of saponin rich fraction from the fruits of Solanum xanthocarpum Schrad. & Wendl.(Solanaceae) against ethylene glycol induced urolithiasis in rats. Journal of Ethnopharmacology. 2012 Oct 31; 144(1): 160-70.

6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009 Jul 21; 339.

7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29; 372.

8. Khan SR, Canales BK, Dominguez-Gutierrez PR. Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation. Nature Reviews Nephrology. 2021 Jun; 17(6): 417-33.

9. Robertson WG. Kidney models of calcium oxalate stone formation. Nephron Physiology. 2004 Oct 1; 98(2): 21-30.

10. Evan A, Lingeman J, Coe FL, Worcester E. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney International. 2006 Apr 2; 69(8):1313-8.

11. Verkoelen CF, Van Der Boom BG, Houtsmuller AB, Schröder FH, Romijn JC. Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. American Journal of Physiology-Renal Physiology. 1998 May 1; 274(5): F958-65.

12. Thamilselvan S, Hackett RL, Khan SR. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. The Journal of Urology. 1997 Mar; 157(3): 1059-63.

13. Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrology Dialysis Transplantation. 2014 Mar 1; 29(3): 507-14.

14. Barr-Beare E, Saxena V, Hilt EE, Thomas-White K, Schober M, Li B, Becknell B, Hains DS, Wolfe AJ, Schwaderer AL. The interaction between Enterobacteriaceae and calcium oxalate deposits. PloS One. 2015 Oct 8; 10(10): e0139575.

15. Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Dietary and lifestyle risk factors associated with incident kidney stones in men and W Türk C, Knoll T, Petrik A, Sarica K, Straub M, Seitz C. Guidelines on urolithiasis. European Association of Urology. 2011 Mar 30.

16. Osman MM, Alfano Y, Kamp S, Haecker A, Alken P, Michel MS, Knoll T. 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy. European Urology. 2005 Jun 1; 47(6): 860-4.

17. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M. Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies.

18. Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: alternative or complementary?. Planta Medica. 2009 Aug; 75(10): 1095-103.

19. Aggarwal A, Tandon S, Singla SK, Tandon C. Diminution of oxalate induced renal tubular epithelial cell injury and inhibition of calcium oxalate crystallization in vitro by aqueous extract of Tribulus terrestris. International Braz J Urol. 2010; 36: 480-9.

20. Chhatre S, Nesari T, Somani G, Kanchan D, Sathaye S. Phytopharmacological overview of Tribulus terrestris. Pharmacognosy Reviews. 2014 Jan; 8(15):45.

21. Anand R, Patnaik GK, Kulshreshtha DK, Dhawan BN. Activity of certain fractions of Tribulus terrestris fruits against experimentally induced urolithiasis in rats. Indian Journal of Experimental Biology. 1994 Aug 1; 32(8): 548-52.

22. Kaushik J, Tandon S, Bhardwaj R, Kaur T, Singla SK, Kumar J, Tandon C. Delving into the Antiurolithiatic potential of Tribulus terrestris extract through–In Vivo Efficacy and Preclinical Safety investigations in Wistar Rats. Scientific Reports. 2019 Nov 4; 9(1): 15969.

23. Prasad AK, Kumar S, Iyer SV, Sudani RJ, Vaidya SK. Pharmacognostical, phytochemical and pharmacological review on Bryophyllum pinnata. International Journal of Pharmaceutical and Biological Archives. 2012 Oct 24; 3(3): 423-33.

24. Ojewole JA. Antinociceptive, anti-inflammatory and antidiabetic effects of Bryophyllum pinnatum (Crassulaceae) leaf aqueous extract. Journal of Ethnopharmacology. 2005 May 13; 99(1): 13-9.

25. Prudente AS, Loddi AM, Duarte MR, Santos AR, Pochapski MT, Pizzolatti MG, Hayashi SS, Campos FR, Pontarolo R, Santos FA, Cabrini DA. Pre-clinical anti-inflammatory aspects of a cuisine and medicinal.

26. Atmani F, Khan SR. Effects of an extract from Herniaria hirsuta on calcium oxalate crystallization in vitro. BJU International. 2000 Apr; 85(6): 621-5.

27. García-Pérez P, Lozano-Milo E, Landin M, Gallego PP. From ethnomedicine to plant biotechnology and machine learning: the valorization of the medicinal plant Bryophyllum sp. Pharmaceuticals. 2020 Dec 4; 13(12): 444.

28. Fürer K, Simões-Wüst AP, von Mandach U, Hamburger M, Potterat O. Bryophyllum pinnatum and related species used in anthroposophic medicine: constituents, pharmacological activities, and clinical efficacy. Planta Medica. 2016 Jul; 82(11/12): 930-41.

29. Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clinical Journal of the American Society of Nephrology. 2006 Nov 1; 1(6): 1269-74.

30. Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. The Journal of Urology. 1996 Sep; 156(3): 907-9.

31. Rosen RC, Catania JA, Althof SE, Pollack LM, O’Leary M, Seftel AD, Coon DW. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology. 2007 May 1; 69(5): 805-9.

32. Aggarwal A, Tandon S, Singla SK, Tandon C. Diminution of oxalate-induced renal tubular epithelial cell injury and inhibition of calcium oxalate crystal deposition in experimental nephrolithiasis by Tribulus terrestris extract. Urol Res. 2010; 38(5): 379-384. doi:10.1007/s00240-010-0290-y.

33. Semalty A, Semalty M, Rawat MS, Franceschi F. Supramolecular phospholipids–polyphenolics interactions: The Phytosome® strategy to improve the bioavailability of phytochemicals. Fitoterapia. 2010 Jul 1; 81(5): 306-14.

Received on 28.05.2026 Revised on 16.06.2026

Accepted on 01.07.2026 Published on 10.07.2026

Available online from July 14, 2026

Res.J. Pharmacology and Pharmacodynamics.2026;18(3):313-324.

DOI: 10.52711/2321-5836.2026.00043

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Agent	Mechanistic Strength	Preclinical Data	Human Data	Translational Potential
Tribulus terrestris	High	Strong	Limited	High
Bryophyllum pinnatum	High	Strong	Low	Moderate-High
Citrus sinensis	Moderate–High	Moderate	Moderate	High